$20.43
2.00%
Nasdaq, Aug 29, 10:00 pm CET

Innoviva Stock price

$20.43
+1.97 10.67% 1M
+2.51 14.01% 6M
+3.08 17.75% YTD
+1.33 6.96% 1Y
+7.00 52.12% 3Y
+8.72 74.47% 5Y
+6.52 46.87% 10Y
+3.91 23.66% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.40 2.00%

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$1.2b
Net debt
positive
Cash
$497.7m
Shares outstanding
63.0m
Valuation (TTM | estimate)
P/E
45.4 | 19.3
P/S
3.5 | 3.3
EV/Sales
3.4 | 3.2
EV/FCF
6.2
P/B
1.8
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$370.2m | $388.0m
EBITDA
$216.5m | $160.0m
EBIT
$176.6m | $163.4m
Net Income
$38.7m | $66.6m
Free Cash Flow
$200.6m
Growth (TTM | estimate)
Revenue
12.0% | 8.2%
EBITDA
33.8% | -17.0%
EBIT
29.9% | -2.1%
Net Income
-73.4% | 184.9%
Free Cash Flow
27.4%
Margin (TTM | estimate)
Gross
86.6%
EBITDA
58.5% | 41.2%
EBIT
47.7%
Net
10.4% | 17.2%
Free Cash Flow
54.2%
Financial Health
Equity Ratio
53.1%
Return on Equity
3.4%
ROCE
16.2%
ROIC
12.9%
Debt/Equity
0.6
More
EPS
$0.5
FCF per Share
$3.2
Short interest
21.9%
Employees
127
Rev per Employee
$2.8m
Show more

Is Innoviva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Innoviva Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Innoviva forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Innoviva forecast:

Buy
89%
Hold
11%

Financial data from Innoviva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
370 370
12% 12%
100%
- Direct Costs 50 50
16% 16%
13%
321 321
11% 11%
87%
- Selling and Administrative Expenses 111 111
1% 1%
30%
- Research and Development Expense 20 20
53% 53%
5%
217 217
34% 34%
58%
- Depreciation and Amortization 40 40
54% 54%
11%
EBIT (Operating Income) EBIT 177 177
30% 30%
48%
Net Profit 39 39
73% 73%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Innoviva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innoviva Stock News

Neutral
Business Wire
6 days ago
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following u...
Neutral
The Motley Fool
26 days ago
Innoviva (INVA -1.03%), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share (GAAP) of $0.77 on $100.3 million in revenue.
More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office United States
CEO Mr. Raifeld
Employees 127
Founded 1996
Website www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today